WATERTOWN, Mass.--(BUSINESS WIRE)--May 17, 2018--Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced that it will present Phase 1 results from a Phase 1/2a study of PEN-221 in patients with neuroendocrine tumors or small cell lung cancer at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting occurring June 1-5, 2018 in Chicago IL.

The data presented will describe the safety, tolerability, pharmacokinetics, and preliminary efficacy of PEN-221, a miniature drug conjugate containing a peptide ligand that is highly selective in targeting the somatostatin receptor 2 (SSTR2) that is conjugated to the potent payload DM1. SSTR2 is a cell surface target that is overexpressed in a variety of solid tumor cancers. PEN-221 is currently being evaluated in a Phase 2a trial in patients with gastrointestinal midgut neuroendocrine tumors, pancreatic neuroendocrine tumors, or small cell lung cancer.

“We are very pleased to have completed the Phase 1 portion of our Phase 1/2a clinical trial for PEN-221 on schedule and to present the data from the Phase 1 trial evaluating PEN-221 at ASCO,” said Drew Fromkin, President and Chief Executive Officer of Tarveda. “We are encouraged by the data from studies of PEN-221 to date and look forward to advancing the Phase 2a portion of the study for PEN-221 as well as our Phase 1 trial for PEN-866.”

Details of the poster presentation are as follows:

Title: First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results. Abstract Number: 4097 Date: June 3, 2018 Time: 8:00 – 11:30 AM CT Location: Hall A

About Pentarins™

Tarveda is developing Pentarins™, potent and selective miniature drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell killing agent through a tuned chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for rapid and deep penetration into the tumor tissue, the ligand’s targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell killing payload inside the cancer cells for efficacy.

About Tarveda Therapeutics, Inc.

Tarveda Therapeutics, Inc. discovers and develops Pentarins™, a new class of potent and selective miniature drug conjugates with enhanced targeting capabilities for the treatment of a wide range of solid tumor cancers. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniature drug conjugate that targets the somatostatin receptor 2 (SSTR2) for treatment of patients with neuroendocrine, small cell lung, prostate, and other cancers that express SSTR2. PEN-221 comprises a highly selective peptide for SSTR2 conjugated to the potent cytotoxic payload, DM1, through a tuned cleavable linker. Tarveda is also advancing its Pentarin HSP90 drug conjugate platform with lead drug candidate PEN-866, which is a miniature drug conjugate that selectively binds to the intracellular target, Heat Shock Protein 90 (HSP90), and is linked to the payload SN-38, the highly potent active metabolite of irinotecan. Tarveda’s strategy includes developing its own proprietary Pentarins as well as applying the Pentarin platform to enhance the effectiveness of the targeting moieties and novel payloads of pharmaceutical collaborators. www.tarveda.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20180517005467/en/

CONTACT: MacDougall Biomedical Communications

George E. MacDougall, 781-235-3060

george@macbiocom.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL

SOURCE: Tarveda Therapeutics, Inc.

Copyright Business Wire 2018.

PUB: 05/17/2018 08:00 AM/DISC: 05/17/2018 08:01 AM

http://www.businesswire.com/news/home/20180517005467/en